Quarterly report [Sections 13 or 15(d)]



>






true


Q1


Allena Pharmaceuticals, Inc.


0001624658


--12-31
< br>

















0001624658




2021-01-01


2021-03-31






0001624658




2021-05-07





xbrli:shares













UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549








FORM


10-Q/A




(Amendment No. 1)








(Mark One)












QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934



For the quarterly period ended

March 31,

2021




OR














TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934



For the transition period from


to




Commission File Number:


001-38268











ALLENA PHARMACEUTICALS, INC.



(Exact name of registrant as specified in its charter)













































Delaware







45-2729920





(State or other jurisdiction of


incorporation or organization)




(I.R.S. Employer


Identification No.)






One Newton Executive Park

,

Suite 202




Newton

,

Massachusetts






02462




(Address of principal executive offices)




(Zip Code)



(

617

)


467-4577




(Registrant’s telephone number, including area code)








Securities registered pursuant to Section 12(b) of the Act:
































Title of each class




Trading


Symbol




Name of each exchange


on which registered




Common Stock, par value $0.001 per share






ALNA






The Nasdaq Global Select Market




Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes

☒    No  ☐


Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation

S-T

(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes

☒    No  ☐


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a

non-accelerated

filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule

12b-2

of the Exchange Act.




























































Large accelerated filer





Accelerated filer









Non-accelerated filer






Smaller reporting company














Emerging growth company







If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.





Indicate by check mark whether the registrant is a shell company (as defined in Rule

12b-2

of the Exchange Act).    Yes  ☐    No





As of May 7, 2021, the registrant had

57,690,060

shares of common stock, $0.001 par value per share outstanding.
















EXPLANATORY NOTE



Allena Pharmaceuticals, Inc. (the “Company”) is filing this Amendment No. 1 (the “Amendment”) on Form

10-Q/A

to amend its Quarterly Report on Form

10-Q

for the quarter ended March 31, 2021, filed with the Securities and Exchange Commission on May 13, 2021 (the “Original

10-Q”),

for the purpose of filing revised versions of Exhibits 31.1 and 31.2 filed with the Original

10-Q.



The Company is filing revised exhibits solely in order to include in the certifications set forth in the Exhibits the language added to the introductory portion of paragraph 4 and the language of revised paragraph 4(b), which language was inadvertently omitted from the certifications when originally filed. The Amendment does not reflect events occurring after the date of the filing of the Original

10-Q

or modify or update any of the other disclosures contained therein in any way. Accordingly, the Amendment should be read in conjunction with the Original

10-Q.

The Amendment consists solely of the preceding cover page, this explanatory note, the signature page and paragraphs 1, 2, 4 and 5 of each of the revised certifications filed as exhibits to the Amendment. Because no financial statements have been included in this Amendment, paragraph 3 of each of the certifications set forth in the Exhibits has been omitted.







1










Item 6. Exhibits


Furnish the exhibits required by Item 601 of Regulation

S-K

(§ 229.601 of this chapter).














































Exhibit


Number




Description




31.1*



Certification of Principal Executive Officer pursuant to Exchange Act rules

13a-14

or

15d-14.





31.2*



Certification of Principal Financial Officer pursuant to Exchange Act rules

13a-14

or

15d-14.





104


Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.









*


Filed herewith.





2










SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.





















































































ALLENA PHARMACEUTICALS, INC.






Date: November 12, 2021




By:



/s/ Louis Brenner









Louis Brenner, M.D.



Chief Executive Officer and Director




(Principal Executive Officer)







Date: November 12, 2021




By:



/s/ Richard Katz









Richard Katz, M.D.



Chief Financial Officer




(Principal Financial and Accounting Officer)






3




The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Allena Pharmaceuticals, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

Statement of acquisition of beneficial ownership by individuals - Jan. 25, 2022
Allena Pharmaceuticals Provides Clinical And Corporate Update ALLN-346, - Jan. 4, 2022

Auto Refresh

Feedback